Sen. Bernie Sanders (I-VT) said on Tuesday that he is making a second run for the White House in 2020. At the top of his policy proposals is “Medicare for all,” which has become a defining issue for Democrats vying for the party’s nomination. (New York Times).

The Supreme Court has ended Maryland’s attempt to reinstate a law that would prevent price gouging by pharmaceutical companies. The High Court on Tuesday declined to take up the state’s appeal of a federal court ruling that struck down the state law. The decision has been called a blow to states’ efforts to rein in drug prices. (Reuters)

A late-stage study has found that a non-opioid painkiller developed by Pfizer and Eli Lilly was effective in reducing chronic lower-back pain when used in stronger doses. However, a lower dose of tanezumab did not alleviate pain compared with a placebo. (Reuters)

Former Celgene CEO Bob Hugin has joined the board of Allergan following a failed Senate run from New Jersey. The company’s leadership has spun Hugin’s arrival as a sign it is willing to revamp its executive structure. (Endpoints)

Ireland’s government is warning residents not to stockpile medicines before Brexit. Ireland relies on the U.K. for many treatments that may not be approved for E.U. use if the U.K. leaves Europe without a deal at the end of March. Ireland’s government said it has stockpiled as much as 12 weeks of virtually all medicines. (Reuters)